Kessling A M, Rajput-Wiliams J, Bainton D, Scott J, Miller N E, Baker I, Humphries S E
Charing Cross Sunley Research Centre, Hammersmith, London.
Am J Hum Genet. 1988 Mar;42(3):458-67.
We have investigated the frequencies of RFLPs of the apolipoprotein (apo) AII gene and of the apo AI-CIII-AIV gene cluster in 109 men, selected from a random sample of 1,910 men aged 45-59 years, to cover a wide range of plasma high-density-lipoprotein (HDL)-cholesterol concentration. There was no significant difference in apo AI or apo AII RFLP allele frequency between groups of individuals with high and low HDL-cholesterol concentration. However, the apo AI PstI RFLP showed an association with genetic variation determining the plasma concentration of apo AI in this sample. Genetic variation in the apo AI-CIII-AIV gene region, as defined by haplotypes, accounted for 16% of the phenotypic variance in the apo AI concentration and for 8% of the phenotypic variance in HDL-cholesterol concentration. There was no significant association between alleles of the apo AII MspI RFLP and genetic variation determining apo AII or HDL concentration. The data demonstrate that genetic variation in the apo AI-CIII-AIV gene cluster is involved in determining the serum concentration of apo AI in this sample of clinically well individuals.
我们从1910名年龄在45至59岁的男性随机样本中选取了109名男性,调查了载脂蛋白(apo)AII基因以及apo AI-CIII-AIV基因簇的限制性片段长度多态性(RFLP)频率,以涵盖广泛的血浆高密度脂蛋白(HDL)胆固醇浓度范围。在HDL胆固醇浓度高和低的个体组之间,apo AI或apo AII的RFLP等位基因频率没有显著差异。然而,在该样本中,apo AI PstI RFLP显示出与决定apo AI血浆浓度的基因变异有关。由单倍型定义的apo AI-CIII-AIV基因区域的基因变异,占apo AI浓度表型变异的16%,占HDL胆固醇浓度表型变异的8%。apo AII MspI RFLP的等位基因与决定apo AII或HDL浓度的基因变异之间没有显著关联。数据表明,在这个临床健康个体样本中,apo AI-CIII-AIV基因簇的基因变异参与了决定apo AI的血清浓度。